GlassScriptPhysician profile
Rania Kaoukis
NPI 1982023925
$4,289.01
in general payments reported to CMS, 2019-2025
31 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.44 · 2020: $75.20 · 2021: $79.71 · 2022: $150 · 2023: $1,245 · 2024: $1,540 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,876.64 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $596.16 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Coroflow, Cardiomems |
| Novartis Pharmaceuticals Corporation | $396.09 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $328.80 | 2020-2025 | Lifevest |
| Medtronic, INC. | $327.03 | 2021-2024 | Onyx Frontier, Symplicity G3 |
| Cvrx, INC. | $275.36 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.90 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $264.52 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $241.35 | 2024-2025 | Opsumit, Uptravi |
| Pfizer INC. | $159.13 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.46 | 2023-2025 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $153.77 | 2023-2025 | Amvuttra |
| Amgen INC. | $130.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $121.56 | 2022-2024 | Xarelto |
| Scpharmaceuticals INC. | $111.41 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.88 | 2024-2025 | Camzyos, Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $102.69 | 2024-2025 | Accucinch |
| Merck Sharp & Dohme LLC | $98.80 | 2023-2025 | Verquvo |
| Philips North America LLC | $74.21 | 2023-2025 | Ecc Solutions, Mcot |
| Lexicon Pharmaceuticals, INC. | $47.58 | 2023 | Inpefa |
| Boston Scientific Corporation | $44.44 | 2025 | Accolade Sr |
| Bayer Healthcare Pharmaceuticals INC. | $43.99 | 2025 | |
| Bridgebio Pharma, INC. | $43.18 | 2025 | Attruby |
| Chiesi USA, INC. | $33.58 | 2023-2024 | Kengreal |
| Esperion Therapeutics, INC. | $26.14 | 2025 | Nexletol |
| Heartflow, INC. | $24.36 | 2024 | |
| Catheter Precision INC. | $23.81 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.75 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $21.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.57 | 2022 | |
| Cashflow Solutions, LLC | $14.80 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Medtronic Vascular, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rania Kaoukis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.